| Project/Area Number |
18K07896
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 53010:Gastroenterology-related
|
|---|
| Research Institution | Asahikawa Medical College |
|---|
Principal Investigator |
Nozu Tsukasa 旭川医科大学, 医学部, 教授 (30312367)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
奥村 利勝 旭川医科大学, 医学部, 教授 (60281903)
|
|---|
| Project Period (FY) |
2018-04-01 – 2022-03-31
|
| Project Status |
Completed (Fiscal Year 2021)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2021: ¥520,000 (Direct Cost: ¥400,000、Indirect Cost: ¥120,000)
Fiscal Year 2020: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2019: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2018: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | 過敏性腸症候群 / 腸管感覚 / 腸管バリアー / メタボリックシンドローム / メタボリック症候群 / サイトカイン / 内臓感覚 / うつ病 / 内臓知覚過敏 / 消化管バリア / CRF / TLR4 / 腸管透過性 |
|---|
| Outline of Final Research Achievements |
Majority of the patients with irritable bowel syndrome (IBS) are known to display visceral hypersensitivity and increased gut permeability. In the present study, we demonstrated that these changes were mediated via CRF, TLR4 and proinflammatory cytokine signaling in rat IBS model. Incidentally, CRF, TLR4 and proinflammatory cytokine signaling have been also reported to be involved in the pathophysiology of metabolic syndrome. We also showed that the drugs used in metabolic syndrome improved these gastrointestinal changes in IBS model, possibly by the suppression of proinflammatory cytokine signaling. These results suggest that IBS and metabolic syndrome may have a similar pathophysiology, which may be a hint for the development of novel therapy of IBS.
|
| Academic Significance and Societal Importance of the Research Achievements |
IBSはQOLを著しく低下させることより欠勤や不登校を高率に生じさせ，社会的にも大きな問題となっている．IBSの治療は多くが対症療法であり，治療選択肢は乏しい．今回の研究により，メタボリックシンドロームとIBSには共通の機序が存在することが明らかとなった．さらにこの知見から，メタボリックシンドロームの治療薬が，IBSでも効果を発揮するのではないかという仮説を建て，実際その仮説が正しいことを明らかにした．これらの結果は，既存のメタボリックシンドローム治療薬が，IBS患者でも効果があることを示唆し，臨床応用のハードルが低い，既存治療薬の適応拡大という新しいIBSの治療アプローチをを提案できた．
|
